Bohui Innovation(SZ:300318)2022-11-21 16:10Group 1: Company Strategy and Development - The company will continue to focus on its core business areas (IVD and biological products) and enhance user satisfaction while increasing investment in new product development over the next two to three years [2][3] - The company aims to accelerate research and development in the health sector, particularly in IVD, and expand its product line and application areas in analytical instruments [3][4] - The company has completed strategic layouts in inspection, biological products, and research equipment, and plans to further develop products and integrate business operations in these areas over the next three to five years [3][4] Group 2: Financial Performance and Challenges - The management is committed to improving company performance and addressing the pressure on earnings through diligent management practices [3][4] - The company has faced challenges due to rising raw material prices but plans to mitigate these impacts through production line upgrades and supply chain management [5][6] - The company has experienced continuous losses in recent years but is focused on developing new technologies and products to enhance market share and core competitiveness [5][6] Group 3: Product Development and Market Position - The company has invested significantly in the development of blood products, with two subsidiaries now producing seven types of blood products, covering important varieties in the market [5][6] - A new blood product production base with a capacity of 1,500 tons is under construction, which will significantly enhance production capabilities and technical levels [5][6] - The company is actively exploring international markets for its COVID-19 testing kits, having obtained CE certification for its products [4][5] Group 4: Corporate Governance and Investor Relations - Shareholder stock reductions are based on personal decisions and do not reflect concerns about the company's future [6][7] - The company emphasizes compliance with regulations and has taken steps to educate management on legal responsibilities following incidents of stock reduction by executives [6][7] - The company is open to hosting investor visits to enhance understanding and gather constructive feedback [7][8]